PREVENT Equations Show Lower ASCVD Risk Than Pooled Cohort Equations
By Elana Gotkine HealthDay Reporter
MONDAY, July 15, 2024 -- The 10-year predicted atherosclerotic cardiovascular disease (ASCVD) risk estimated by the Predicting Risk of cardiovascular disease EVENTs (PREVENT) equations is about half that estimated by the pooled cohort equations (PCEs) among adults with stage 1 hypertension, according to a study published online July 15 in Hypertension.
Paul Muntner, Ph.D., from the University of Alabama at Birmingham, and colleagues examined U.S. National Health and Nutrition Examination Survey data from 2013 to 2020 for 1,703 adults aged 30 to 79 years with stage 1 hypertension and without self-reported cardiovascular disease. Ten-year ASCVD risk was estimated by the PCEs and by the base PREVENT equations.
The researchers found that the mean 10-year ASCVD risk was 5.4 and 2.9 percent using the PCEs and PREVENT equations, respectively. The proportion with a 10-year ASCVD risk of 10 to <15 percent and ≥15 percent was 8.1 and 7.8 percent, respectively, when estimated by the PCEs, and 3.0 and 0.3 percent, respectively, when estimated by the PREVENT equations. None of the participants had a 10-year ASCVD risk ≥10 percent on the PREVENT equations and <10 percent on the PCEs, while 12.5 percent had a 10-year ASCVD risk ≥10 and <10 percent on the PCEs and PREVENT equations, respectively. Compared with the mean 10-year ASCVD risk on the PCEs, the mean 10-year total cardiovascular disease risk estimated by the PREVENT equations was lower.
"A high percentage of U.S. adults with stage 1 hypertension may not be recommended initiation of antihypertensive medication if a 10-year ASCVD risk is estimated by the PREVENT equations instead of the PCEs," the authors write.
One author disclosed ties to MedExplain, a patient education company.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Hypertensive Disorders of Pregnancy Adversely Affect Preemie Neurodevelopment
THURSDAY, May 1, 2025 -- Maternal hypertensive disorders of pregnancy (HDP) are associated with adverse cognitive and language development in preterm infants at 2 years' corrected...
Lorundrostat Beneficial for BP Reduction in Uncontrolled Hypertension
WEDNESDAY, April 30, 2025 -- For patients with uncontrolled and treatment-resistant hypertension, lorundrostat is associated with greater reductions in blood pressure than...
Intensive BP Reduction Effective for Lowering All-Cause Dementia Risk
TUESDAY, April 29, 2025 -- An intensive blood pressure (BP) reduction intervention is effective for lowering the risk for all-cause dementia among individuals aged 40 years and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.